compasstherapeutics.com (CMPX) - Debt to Equity

The investment attractiveness of Compass Therapeutics (CMPX) is based on stable demand in immuno-oncology that remains independent of market cycles. The history of the company's leverage ratio visualizes financial stability, where 0.06 characterizes this valuation parameter. Growth is driven by alliances with laboratories and patent acquisitions, while security is confirmed by sufficient liquidity reserves to cover the costs of developing tumor-fighting antibodies.

Investors use this ratio to assess the issuer's degree of financial dependence on borrowed funds. The metric is calculated as the ratio of total liabilities to equity. By analyzing the current total liabilities-to-equity level, one can judge the balance between risk and expansion. The low leverage of Compass Therapeutics (CMPX) confirms the stability of its specialized clinical trial logistics. The diversification of biocomponents minimizes the need for expensive external financing.